PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
See Details +
This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
See Details +
On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
Beijing Amet was recognized as a "specialized, special and new" enterprise
On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.
See Details +
On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.
Professor Antonio Meeks was elected as a foreign academician of the Chinese Academy of Engineering
According to the announcement issued by the Chinese Academy of Engineering today, the 2021 academician co-election of the Chinese Academy of Engineering has been completed recently, and a total of 84 academicians of the Chinese Academy of Engineering and 20 foreign academicians of the Chinese Academy of Engineering have been elected. Professor Antonio Meeks was elected as a foreign academician of the Chinese Academy of Engineering
See Details +
According to the announcement issued by the Chinese Academy of Engineering today, the 2021 academician co-election of the Chinese Academy of Engineering has been completed recently, and a total of 84 academicians of the Chinese Academy of Engineering and 20 foreign academicians of the Chinese Academy of Engineering have been elected. Professor Antonio Meeks was elected as a foreign academician of the Chinese Academy of Engineering
Beijing Amet Company successfully obtained 2 national trademark registration certificates
Recently, our company applied for registration of the trademarks "Amet PERISORB" and "PERISORB", and successfully obtained the trademark certificate issued by the State Intellectual Property Office. These two trademarks will be mainly used for the fully degradable peripheral vascular drug-eluting stent system products developed by our company using independent innovative 3D printing technology.
See Details +
Recently, our company applied for registration of the trademarks "Amet PERISORB" and "PERISORB", and successfully obtained the trademark certificate issued by the State Intellectual Property Office. These two trademarks will be mainly used for the fully degradable peripheral vascular drug-eluting stent system products developed by our company using independent innovative 3D printing technology.
Beijing Amet's patent application was authorized by the European Patent Office
Recently, the European patent application "MODIFIED BIODEGRADABLE AND MEDICAL POLYMER DEVICES AND A METHOD FOR PREPARING THE SAME" submitted by Beijing Amet was authorized by the European Patent Office (European Patent Application No. 16900812.5). The application and authorization of this invention patent further demonstrates the confidence and strength of Amet's technological innovation and participation in international competition.
See Details +
Recently, the European patent application "MODIFIED BIODEGRADABLE AND MEDICAL POLYMER DEVICES AND A METHOD FOR PREPARING THE SAME" submitted by Beijing Amet was authorized by the European Patent Office (European Patent Application No. 16900812.5). The application and authorization of this invention patent further demonstrates the confidence and strength of Amet's technological innovation and participation in international competition.
The project that Beijing Amet participated in won the second prize of the Science and Technology Award of the Chinese Society of Biomaterials
Recently, the "Key Technologies for Design and Manufacture of Biodegradable Implantable Interventional Medical Devices" project, led by Professor Fan Yubo, Dean of the School of Biological and Medical Engineering, Beihang University, and participated by Beijing Natong Medical and Beijing Amat, won the Chinese Society of Biomaterials. Second Prize of Science and Technology Award. At the opening ceremony of the China Biomaterials Conference held at the Shanghai International Convention Center on October 12, 2021, Professor Fan Yubo accepted the award certificate issued by Academician Liu Changsheng on behalf of the Society on behalf of the project team.
See Details +
Recently, the "Key Technologies for Design and Manufacture of Biodegradable Implantable Interventional Medical Devices" project, led by Professor Fan Yubo, Dean of the School of Biological and Medical Engineering, Beihang University, and participated by Beijing Natong Medical and Beijing Amat, won the Chinese Society of Biomaterials. Second Prize of Science and Technology Award. At the opening ceremony of the China Biomaterials Conference held at the Shanghai International Convention Center on October 12, 2021, Professor Fan Yubo accepted the award certificate issued by Academician Liu Changsheng on behalf of the Society on behalf of the project team.
Beijing Amet Biodegradable Peripheral Vascular Drug-Eluting Stent System Approved by NMPA for Registration Clinical Trial Study
Recently, PeriSorb™, a fully degradable peripheral vascular drug-eluting stent system independently developed by Beijing Amet, has been approved to carry out registration clinical trials after the review and approval of the Medical Device Technology Review Center of the National Medical Products Administration (NMPA). https://www.cmde.org.cn/CL0191/23968.html?WxUg5ztDmi=1629961936649). This clinical trial will be launched in a number of tertiary hospitals across the country in the near future. This is the second fully degradable drug-eluting stent to enter clinical research after the company's fully degradable coronary drug-eluting stent (AMSorb®) launched a large-scale randomized controlled clinical trial.
See Details +
Recently, PeriSorb™, a fully degradable peripheral vascular drug-eluting stent system independently developed by Beijing Amet, has been approved to carry out registration clinical trials after the review and approval of the Medical Device Technology Review Center of the National Medical Products Administration (NMPA). https://www.cmde.org.cn/CL0191/23968.html?WxUg5ztDmi=1629961936649). This clinical trial will be launched in a number of tertiary hospitals across the country in the near future. This is the second fully degradable drug-eluting stent to enter clinical research after the company's fully degradable coronary drug-eluting stent (AMSorb®) launched a large-scale randomized controlled clinical trial.
